Genitourinary Cancers | Specialty

The OncLive Genitourinary Cancer condition center page is a comprehensive resource for clinical news and expert insights across genitourinary (GU) malignancies, including renal cell carcinoma, urothelial carcinoma, and prostate cancer. This section features news articles, interviews in written and video format, and podcasts that focus on the evolving treatment paradigm of GU cancers and emerging research.

Dr. Clark on the Role of Cytoreductive Nephrectomy in RCC

November 27th 2018

Peter Clark, MD, medical oncologist, Levine Cancer Institute, Atrium Health, discusses the role of cytoreductive nephrectomy in the treatment of patients with renal cell carcinoma (RCC).

Dr. Choueiri on Checkpoint Inhibitor/TKI Combinations in RCC

November 22nd 2018

Toni Choueiri, MD, director, Lank Center for Genitourinary Oncology, director, Kidney Cancer Center, Jerome and Nancy Kohlberg Associate Professor of Medicine, Harvard Medical School, Dana-Farber Cancer Institute, discusses combinations of checkpoint inhibitors and TKIs for the treatment of renal cell carcinoma.

Dr. Rosenberg Discusses Challenges in Metastatic Urothelial Carcinoma

November 20th 2018

Jonathan E. Rosenberg, MD, medical oncologist, chief, Genitourinary Medical Oncology Service, Memorial Sloan Kettering Cancer Center, discusses challenges in the treatment of patients with metastatic urothelial carcinoma.

Choueiri Highlights Promising Avelumab/Axitinib Data in RCC

November 20th 2018

Toni K. Choueiri, MD, discusses the JAVELIN Renal 101 study and where these data fit into the complex treatment paradigm of renal cell carcinoma.

Dr. Figlin on Treatment Strategies in Advanced RCC

November 20th 2018

Robert A. Figlin, MD, director, Division of Hematology/Oncology, Steven Spielberg Professor of Biomedical Sciences and Medicine, Cedars-Sinai Medical Center, discusses treatment strategies for patients with advanced renal cell carcinoma.

Nivolumab/Ipilimumab Combo Nears EU Approval for Frontline RCC

November 17th 2018

The European Medicines Agency’s Committee for Medicinal Products for Human Use recommended approval of nivolumab combined with low-dose ipilimumab as a frontline treatment for patients with intermediate- and poor-risk advanced renal cell carcinoma.

Dr. de Wit Discusses Findings With Pembrolizumab in NMIBC

November 17th 2018

Ronald de Wit, MD, PhD, group leader, Experimental Systematic Therapy of Urogenital Cancers program, Erasmus MC Cancer Institute, Rotterdam, Netherlands, discusses findings with pembrolizumab (Keytruda) in non-muscle invasive bladder cancer.

Dr. McDermott on an Analysis of the CheckMate-214 Study in RCC

November 14th 2018

David F. McDermott, MD, director of the Biologic Therapy Program at Beth Israel Deaconess Medical Center, discusses an analysis of the CheckMate-214 study in advanced renal cell carcinoma (RCC).

Dr. Powles on Biomarkers for Immunotherapy in Bladder Cancer

November 14th 2018

Thomas Powles MBBS, MRCP, MD, professor of Genitourinary Oncology, lead, Solid Tumour Research, Barts Cancer Institute, director, Barts Cancer Centre, discusses biomarkers for immunotherapy in bladder cancer.

Dr. Choueiri on Biomarkers in RCC

November 14th 2018

Toni Choueiri, MD, director, Lank Center for Genitourinary Oncology, director, Kidney Cancer Center, Jerome and Nancy Kohlberg Associate Professor of Medicine, Harvard Medical School, Dana-Farber Cancer Institute, discusses biomarkers in renal cell carcinoma.

Rosenberg Reflects on Immunotherapy Developments in Urothelial Carcinoma

November 10th 2018

Jonathan E. Rosenberg, MD, discusses the extended follow-up of the CheckMate-032 study, as well as the future of immunotherapy in urothelial carcinoma.

Redefining the Role of Cytoreductive Nephrectomy in RCC

November 10th 2018

Peter E. Clark, MD, discusses the role of surgery in the rapidly evolving treatment paradigm for patients with renal cell carcinoma.

Dr. Rini on Molecular Characteristics of the IMmotion151 Study in RCC

November 7th 2018

Brian I. Rini, MD, professor of medicine, Cleveland Clinic, discusses the molecular characteristics of patients with renal cell carcinoma (RCC) enrolled on the IMmotion151 study.

Prodrugs in Oncology: Teaching Old and New Drugs More Tricks

November 7th 2018

As researchers gain a better understanding of the unique aspects of individual tumor types and their surrounding microenvironment, the design of novel therapies categorized as prodrugs is become increasingly sophisticated, and several novel constructs show particular promise.

Tivozanib Improves PFS in Highly Refractory RCC

November 6th 2018

The VEGF inhibitor tivozanib reduced the risk of disease progression or death by 26% compared with sorafenib in patients with highly refractory advanced or metastatic RCC, according to topline findings from the phase III TIVO-3 trial.

Dr. Meeks on Mutations Associated With T1 Progression in Bladder Cancer

November 6th 2018

Joshua J. Meeks, MD, PhD, assistant professor of urology, Northwestern University Feinberg School of Medicine, discusses the mutations associated with T1 progression in bladder cancer.

Dr. Amin on Evaluating Response to Immunotherapy in RCC

November 3rd 2018

Asim Amin, MD, PhD, director of immunotherapy, Levine Cancer Institute, discusses methods of evaluating response to immunotherapy in renal cell carcinoma (RCC).

Frontline Paradigm Continues to Evolve in RCC

November 2nd 2018

Claud M. Grigg, Jr, MD, discusses the evolving treatment options in the frontline setting for patients with renal cell carcinoma.

Lead Investigator Highlights Pembrolizumab Potential in BCG-Resistant Bladder Cancer

November 2nd 2018

Ronald de Wit, MD, PhD, discusses the clinical implications of pembrolizumab in the non–muscle invasive bladder cancer patient population.

Dr. O'Donnell on PD-L1 Testing in Bladder Cancer

November 2nd 2018

Peter O’Donnell, MD, associate professor of medicine, University of Chicago Medicine, discusses PD-L1 testing in patients with bladder cancer.

NEXT PAGE
PREVIOUS PAGE